Liraglutide as Additional T t t i T 1 Di b tTreatment in Type 1 Diabetes
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, AntoineMakdissi, Sandeep Dhindsa, Ajay Chaudhuri and
P h D dParesh Dandona
Division of Endocrinology Diabetes and MetabolismDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo
"J.L." before insulin on December 7, 1922 (15 pounds) and after insulin on February 26, 1923 (30 pounds).
*
Incretin Effect*
**
* **
*
St d dStandard Deviation decreased
average of 20 gmg/dl
1) DFPre-VictozaHBA1C = 7.4
On Victoza
Post Victoza
The Pathogenesis of Type 2 DiabetesThe Pathogenesis of Type 2 DiabetesBetaBeta--Cell Workload Outpaces BetaCell Workload Outpaces Beta--Cell ResponseCell ResponseThe Pathogenesis of Type 2 DiabetesThe Pathogenesis of Type 2 DiabetesBetaBeta--Cell Workload Outpaces BetaCell Workload Outpaces Beta--Cell ResponseCell Response
Healthy Subjects (n = 14)
Beta-CellWorkload Beta-CellWorkload
Type 2 Diabetes (n = 12)
Beta-CellWorkload Beta-CellWorkload
Carbohydrate Meal
Beta-CellResponse Beta-CellResponse
WorkloadWorkload
Beta-CellResponse Beta-CellResponse
WorkloadWorkload
Beta-Cell Beta-Cell
ResponseResponse
Beta-Cell Beta-Cell
ResponseResponse
Beta-CellWorkload Beta-CellWorkload Beta-CellWorkload Beta-CellWorkload
EuglycemiaEuglycemiaEuglycemiaEuglycemiaHyperglycemiaHyperglycemia
Mean (SE)
3) KGPre Vi tVictozaA1C 6.5
O Vi tOn Victoza